MiMedx at SAWC Spring 2014: Multiple Studies And Clinical Experience Demonstrate Clinical And Cost Effectiveness Of EpiFix

     MiMedx at SAWC Spring 2014: Multiple Studies And Clinical Experience
Demonstrate Clinical And Cost Effectiveness Of EpiFix Allograft For Treatment
                            Of Hard-to-Heal Wounds

EpiFix® is shown to promote rapid healing and return to function for patients
and provide a potential for significant cost savings.

PR Newswire

MARIETTA, Ga., April 23, 2014

MARIETTA, Ga., April 23, 2014 /PRNewswire/ -- EpiFix®, dehydrated human
amnion/chorion membrane (dHACM) allografts, were shown to be clinically and
cost effective in the treatment of multiple hard-to-treat wounds like diabetic
foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PUs),
according to data and case experiences being presented at the Spring Symposium
on Advanced Wound Care, the leading national wound healing conference now in
its 27^th year. The symposium begins today, April 23, 2014, and concludes on
April 27, 2014.

"We are pleased that two abstracts highlighting EpiFix® allografts were
selected for oral presentation and one of them, authored by Charles M. Zelen,
DPM, FACFAS, FACFAOM, FAPWCA; Thomas E. Serena MD, FACS and Robert J. Snyder,
DPM, MSc, CWS, was selected as 3^rd place for Best Oral Abstract," said Parker
H. "Pete" Petit, CEO of MiMedx Group, Inc. (NASDAQ: MDXG).

"Clinically, EpiFix® is associated with more rapid healing and prevention of
longer term complications including infection and amputation," said Dr.
Stephen Bergquist, Medical Director for Jackson-Madison County Hospital.
"From the cost-of-care perspective, EpiFix requires the use of fewer grafts
leading to overall cost savings," he continued.

Abstracts presenting EpiFix® studies and cases are:

  oA Prospective, Randomized, Comparative Study of Weekly vs. Bi-weekly
    Application of Dehydrated Human Amnion/Chorion Membrane Allograft in the
    Management of Diabetic Foot Ulcers (Abstract #CR_055, Zelen, Serena,
    Snyder) demonstrated in a 12-week study period of 40 patients with a mean
    time to complete healing of 2.4 weeks for weekly application of EpiFix®
    vs. 4.1 wks for biweekly application of EpiFix®. This shows using EpiFix®
    weekly heals DFUs almost twice as fast as biweekly applications of
    EpiFix®. Overall complete heal rate with EpiFix® in both arms was 92.5%
    (37/40) at 12 weeks.



  oA Multi-center Randomized Controlled Clinical Trial Evaluating Two
    Application Regimens of Dehydrated Human Amniotic Membrane and Standard of
    Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers
    (Abstract #CS_139,Serena, Fetterolf , Harris, Doner, Patel, Connell,
    DeMarco, LE, McConnell , Lullove, Taffe.) 90 patients were enrolled to
    date in this ongoing trial. At time of interim analysis 68 patients had
    completed the study: 44 ulcers were randomized to receive dHACM (1 or 2
    applications) and 24 received SOC alone. Outcomes were similar within the
    dHACM group. At 4 weeks, 63.6% of wounds in the dHACM group, and 25.0%
    of the standard of care group demonstrated greater than 40% wound closure
    at 4 weeks (p=0.0023). After 4 weeks ulcers treated with dHACM had reduced
    by 48.9% vs 12.0% for those treated with SOC only, p=0.003.



  oTreatment of Stage III and Stage IV Pressure Ulcers with Dehydrated Human
    Amnion/Chorion Membrane (Abstract #CS_014, Bergquist) evaluated the
    clinical and cost effectiveness of dHACM allografts as a treatment for
    Stage III and IV pressure ulcers (PUs). In Stage III cases and Stage IV
    cases, PUs of varying sizes were completely healed within weeks (from 1
    week for Stage III PUs with wound size of 8.6cm^2 and 2.53 cm^2, to 8
    weeks for a Stage IV PU with an initial wound size of 9.2 cm^2 ). Cost
    effectiveness of dHACM for treatment of PUs was influenced by increased
    healing rates, velocity of healing and subsequent reduction in risk for
    complications. Wound size-appropriate grafts further reduce waste and
    cost per treatment.



  oHuman Amniotic Membrane Allograft to Treat Diabetic Foot Ulcers with
    Exposed Bone and Tendon (Abstract# CS_117 Pougatsch, Shum, Belczyk,
    Rogers) 5 consecutive diabetic neuropathic patients exhibiting wounds with
    exposed bone and tendon were treated with EpiFix® with the intent to gain
    as much coverage over the exposed deep structures in as little time as
    possible in preparation for split-thickness skin grafting. All 5 patients
    had sufficiently developed granulation tissue overlying bone and tendon
    structures and were ready for split-thickness skin grafting in an average
    of 15 days (range 9-22). 4 patients healed the split-thickness skin
    grafts.



"These data support our previously published studies relating to the
significant role for EpiFix® in advanced wound care," said Bill Taylor,
President and COO of MiMedx. MiMedx is the leading developer and manufacturer
of patent protected regenerative biomaterials and bioimplants processed from
human amniotic membrane.

MiMedx is exhibiting at the conference (booth 1506), and will host In-Booth
Education with speakers Steve Bergquist, MD presenting on 'Complex wounds and
pressure ulcer treatment with EpiFix', and Donna Becker, MSN, ACNP-BC who will
discuss 'Clinical experiences with dHACM.' Drs. Robert Snyder, Chuck Zelen,
Matthew Garoufalis and Thomas Serena will be presenting about Wound
Regeneration at a Company-sponsored symposium.

About EpiFix®

EpiFix^® is a human amniotic allograft tissue offering uniquely processed
through the Company's proprietary PURION® Process. EpiFix^® dehydrated human
amnion/chorion membrane (dHACM) can reduce inflammation and reduce scar tissue
formation for enhanced healing. With a variety of sizes available, EpiFix^®
minimizes graft waste. The Company's PURION^® Process combines cleaning,
dehydration and sterilization,  making  EpiFix^® a safe, sterilized tissue
that may be stored at ambient conditions for up to 5 years.

About MiMedx

MiMedx® is an integrated developer, manufacturer and marketer of patent
protected regenerative biomaterial products and bioimplants processed from
human amniotic membrane. "Innovations in Regenerative Biomaterials" is the
framework behind our mission to give physicians products and tissues to help
the body heal itself. Our biomaterial platform technologies include AmnioFix®
and EpiFix®, our tissue technologies processed from human amniotic membrane
that is derived from donated placentas. Through our donor program, mothers
delivering full-term Caesarean section births can elect in advance of delivery
to donate the placenta in lieu of having it discarded as medical waste. We
process the human amniotic membrane utilizing our proprietary PURION® Process,
to produce a safe and effective implant. MiMedx® is the leading supplier of
amniotic tissue, having supplied over 225,000 allografts to date for
application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and
Dental sectors of healthcare.

SOURCE MiMedx Group, Inc.

Website: http://www.mimedx.com
Contact: Michael Senken, Phone: (770) 651-9100
 
Press spacebar to pause and continue. Press esc to stop.